Direct-to-Patient (DTP) models are rapidly becoming a prominent topic across the pharmaceutical industry. Yet the central question facing manufacturers is no longer whether DTP is real or here to stay. Instead, organizations must determine whether DTP is the right strategic fit for their specific portfolio.

While some companies may benefit from significant investment in DTP infrastructure, others may find that a more limited compliance-focused approach better aligns with their products, economics, and patient populations.

Much of the recent discussion around DTP has focused on whether the trend represents a structural transformation in healthcare delivery or a temporary response to political and market pressures. Evidence suggests that several long-term factors—including growing enrollment in high-deductible health plans, increasing consumer expectations, and demand for more convenient healthcare experiences—are creating durable support for direct access models.

At the same time, pharmaceutical companies are taking markedly different approaches to DTP. While participation is becoming increasingly common, the depth of investment varies significantly. Some organizations are building comprehensive strategic platforms that integrate patient support, fulfillment, and care pathways. Others are implementing more limited solutions designed primarily to satisfy access requirements.

The distinction ultimately comes down to portfolio fit. Products with the right combination of market characteristics, patient demand, telehealth suitability, and economic viability may justify deeper investment. Others may not.

To help organizations navigate these decisions, A&M developed a framework that evaluates market dynamics, DTP feasibility, patient behavior, and commercial economics to identify where DTP investment can create sustainable value.

The future of DTP will not be determined by industry trends alone. Success will depend on whether organizations can align their investment strategy with the realities of their portfolio, patients, and market opportunity.

This report provides a practical framework for assessing those opportunities and determining whether to invest, comply, or prepare for future evolution in the DTP landscape.

Download the full report to explore A&M's decision framework for Direct-to-Patient investment by pharma.

READ MORE